Back to results

(GSK)

Buy:
1,954.50 p
Sell:
1,954.00 p
Change:
41.00 (2.14%)
Open an account

GSK (GSK)

GSK

ISIN:

GB00BN7SWP63

Sector:

Pharmaceuticals & Biotechnology

Trading on:

London Stock Exchange

Buy:
1,954.50 p
Sell:
1,954.00 p
Change:
41.00 (2.14%)
Updated at: 16-07-2026 - 17:30
*Prices delayed by at least 15 minutes
At a glance

At a glance performance and information

Trading update:

Opening price:

1,904.00 p

Previous close:

1,956.00 p

Day High / Low:

1,958.00 p - 1,896.00 p

52 week High / Low:

2,208.00 p - 1,344.00 p

Volume:

5,092,652

Fundamentals:

Market capitalisation (m):

£ 79,127.93

Shares in issue (m):

4,045

P/E ratio / PEG:

11.53 / 1.45

EPS:

N/A

Currency:

GBP

Dividends:

Last dividend:

GBX 17.0000 (09/07/2026)

Dividend yield:

3.33%

Next dividend:

N/A

Ex-Dividend date:

N/A

Click to see dividend history

Eligibility:

Share Dealing Account
ISA
SIPP

Investing for longer increases the likelihood of positive returns. Over a period of 5 years or more, investments usually give you a higher return compared to cash savings. But investments can go down as well as up in value. So you could get back less than you put in.

Intraday 1 W 1 M 3 M 6 M YTD 1 Y 3 Y 5 Y Max
Advanced Chart
Recent Trades
Dividends
Financials

In the news

image of the news GSK rectal cancer drug shows positive result in key trial
GSK rectal cancer drug shows positive result in key trial
image of the news GSK hails 'milestone' drug trial results in China
GSK hails 'milestone' drug trial results in China
image of the news GSK's momelotinib receives orphan drug designation from US and EU watchdogs
GSK's momelotinib receives orphan drug designation from US and EU watchdogs
image of the news GSK to buy Boston-based biopharma firm Nuvalent for $10.6bn
GSK to buy Boston-based biopharma firm Nuvalent for $10.6bn
image of the news Trials show GSK drug cures hepatitis B in nearly 20% of patients
Trials show GSK drug cures hepatitis B in nearly 20% of patients
image of the news Citi sees buying opportunity at AstraZeneca after recent falls
Citi sees buying opportunity at AstraZeneca after recent falls
image of the news GSK strikes agreement with China's SBP Group, launches final tranche of buyback programme
GSK strikes agreement with China's SBP Group, launches final tranche of buyback programme
image of the news Sales jump at GSK on strong demand for specialty drugs
Sales jump at GSK on strong demand for specialty drugs
image of the news GSK hepatitis B drug secures FDA priority review
GSK hepatitis B drug secures FDA priority review
image of the news US court rules against GSK in dispute with AnaptysBio
US court rules against GSK in dispute with AnaptysBio
image of the news GSK's Blenrep gets green light from China's NMPA
GSK's Blenrep gets green light from China's NMPA
image of the news GSK ovarian, womb cancer drug posts positive results in early trial
GSK ovarian, womb cancer drug posts positive results in early trial
image of the news GSK's Exdensur gets green light from Chinese regulator
GSK's Exdensur gets green light from Chinese regulator
image of the news GSK asthma drug given green light in China
GSK asthma drug given green light in China
image of the news GSK submits bepirovirsen for EMA review after trials hit primary endpoints
GSK submits bepirovirsen for EMA review after trials hit primary endpoints
image of the news GSK treatment wins orphan drug designation in Japan
GSK treatment wins orphan drug designation in Japan
image of the news GSK treatment wins orphan drug designation in Japan
GSK treatment wins orphan drug designation in Japan
image of the news GSK's cholestatic pruritus treatment Lynavoy gets US FDA approval
GSK's cholestatic pruritus treatment Lynavoy gets US FDA approval
image of the news FDA expands approved age indication for GSK RSV vaccine in higher risk adults
FDA expands approved age indication for GSK RSV vaccine in higher risk adults
image of the news GSK strikes global licensing deal with Alfasigma
GSK strikes global licensing deal with Alfasigma
image of the news GSK secures Japan and China reviews for two late‑stage liver disease treatments
GSK secures Japan and China reviews for two late‑stage liver disease treatments
image of the news GSK to acquire Canada's 35Pharma for $950m
GSK to acquire Canada's 35Pharma for $950m
image of the news GSK's Exdensur gets green light from European Commission
GSK's Exdensur gets green light from European Commission
image of the news China's CDE accepts GSK's regulatory filing for RSV vaccine
China's CDE accepts GSK's regulatory filing for RSV vaccine
image of the news JP Morgan raises target price on GSK
JP Morgan raises target price on GSK
image of the news Director dealings: GSK chairman raises stake
Director dealings: GSK chairman raises stake
image of the news EU gives GSK's Nucala green light for use in uncontrolled COPD
EU gives GSK's Nucala green light for use in uncontrolled COPD
image of the news GSK sees slower sales growth in 2026 as patent loss looms
GSK sees slower sales growth in 2026 as patent loss looms
image of the news GSK to cut up to 350 R&D jobs across UK, US
GSK to cut up to 350 R&D jobs across UK, US
image of the news Citi starts AstraZeneca at 'buy', takes 'neutral' stance on GSK
Citi starts AstraZeneca at 'buy', takes 'neutral' stance on GSK
image of the news GSK vaccine given green light for all adults in Europe
GSK vaccine given green light for all adults in Europe
image of the news GSK to snap up Rapt Therapeutics in $2.2bn deal
GSK to snap up Rapt Therapeutics in $2.2bn deal
image of the news GSK chronic hepatitis B treatment hits goal in two studies
GSK chronic hepatitis B treatment hits goal in two studies

RNS

image of the news Director/PDMR Shareholding
Director/PDMR Shareholding
image of the news GSK completes acquisition of Nuvalent, Inc
GSK completes acquisition of Nuvalent, Inc
image of the news Director/PDMR Shareholding
Director/PDMR Shareholding
image of the news Director/PDMR Shareholding
Director/PDMR Shareholding
image of the news Positive Jemperli data in dMMR/MSI-H rectal cancer
Positive Jemperli data in dMMR/MSI-H rectal cancer
image of the news Hansoh positive Phase III results for Riz-Rez
Hansoh positive Phase III results for Riz-Rez
image of the news Director/PDMR Shareholding
Director/PDMR Shareholding
image of the news Directorate change
Directorate change
image of the news Total Voting Rights
Total Voting Rights
image of the news Transaction in Own Shares
Transaction in Own Shares
image of the news Holding(s) in Company
Holding(s) in Company
image of the news Holding(s) in Company
Holding(s) in Company
image of the news Director/PDMR Shareholding
Director/PDMR Shareholding
image of the news GSK announces tender offer to acquire Nuvalent
GSK announces tender offer to acquire Nuvalent
image of the news Director/PDMR Shareholding
Director/PDMR Shareholding
image of the news Transaction in Own Shares
Transaction in Own Shares
image of the news cUTI oral antibiotic Tebipenem approved by US FDA
cUTI oral antibiotic Tebipenem approved by US FDA